Analyst PT cuts, institutional outflows, buybacks, layoffs and 2026 guidance cut pressuring shares
Key Questions
What is the current trading range and key valuation metrics for Novo Nordisk (NVO) stock?
Novo Nordisk stock is trading near lows at $36.67-37.03, down 50% over 12 months and 65% from peak. It has a forward P/E of 1.68, ROE of 60.7%, and dividend yield of 4.87%, with technical analysis support at $35.50-37.50.
Why has Novo Nordisk's stock price declined significantly?
The stock has faced pressure from analyst price target cuts, institutional outflows, a Q1 earnings miss, 5-13% sales drop due to generics and CagriSema competition, 2026 guidance cut, layoffs, and a recent plunge wiping $50 billion off its market value.
What recent layoffs have been announced at Novo Nordisk?
Novo Nordisk has slashed 9,000 jobs amid sales hits in its fat jab business like Ozempic. A new CEO, Doustdar, is overseeing manufacturing scale-up alongside these cuts.
What does investor Lars Hytting predict regarding future layoffs at Novo Nordisk?
Investor Lars Hytting expects another round of layoffs affecting around 4,500 employees, aiming for DKK 8 billion in savings.
What is the status of Novo Nordisk's DKK 15 billion share buyback program?
As of April 1, 2026, Novo Nordisk has repurchased 9,967,992 B shares at an average price of DKK 259.47, totaling DKK 2.59 billion spent in the program.
Is Novo Nordisk considered undervalued by some investors?
Retail investors view the stock as 'terribly undervalued,' with one analysis suggesting it is 66% undervalued. Contrarian buys are occurring despite institutional outflows.
What are the analyst price targets for Novo Nordisk stock?
Analysts have set a price target of $47, implying 27% upside from current levels around $36.67-37.03.
What institutional activity is occurring with Novo Nordisk shares?
Despite outflows pressuring shares, institutions like RPG Investment Advisory LLC and Aberdeen Group plc have acquired shares, with major holders including Loomis Sayles & Co L P owning 17.14 million shares.
$36.67-37.03 near lows (-50% 12mo/-65% peak, fwd P/E 1.68/ROE 60.7%/div 4.87%, AAII Value C); retail 'terribly undervalued'; Q1 miss, 5-13% sales drop, generics/CagriSema; 9000 layoffs/new CEO Doustdar, Lars Hytting predicts ~4500 more; buyback DKK15B prog; PT $47/66% undervalued; contrarian buys vs outflows; Trump tariff war pushing NVO/EU rethink US capex/investments amid IRA/pricing threats.